Key result
Telmisartan effectively treats hypertension with dual ARB and PPARγ activity, offering metabolic repurposing potential.
Why the study?
To provide an overall understanding of telmisartan as an antihypertensive drug and highlight its synthetic methodology, mechanisms of action, and repurposing potential.
This review highlights the synthetic pathways and pharmacological mechanisms of telmisartan, emphasizing its dual action and potential for repurposing beyond hypertension.
Telmisartan’s dual ARB-PPARγ activity may support repurposing exploration in metabolic disease; leaves open clinical adoption pending prospective trials.
Telmisartan is a benzimidazole derivative and a well-known drug to treat hypertension. This is an angiotensin II receptor blocker (ARB) which helps to relax blood vessels. Studies have shown that telmisartan is effective in reducing cardiovascular disease, with a safety and efficacy profile. This review paper provides an overall understanding of telmisartan as an antihypertensive drug. The goal is to highlight the synthetic methodology of telmisartan, from its first synthesis in 1993. This review also discusses its two mechanisms of action: the Renin-Angiotensin-Aldosterone System (RAAS) inhibitor and partial agonist activity at the Peroxisome Proliferator-activated receptor gamma (PPARγ) receptor. Effective repurposing of this drug for various diseases like chronic kidney illness, diabetes, fatty liver, and Alzheimer's has also been discussed.
No takes yet. Share an insight, caveat, or question.
Megha et al. (2026) conducted a review in Hypertension. Telmisartan was evaluated. Telmisartan is an angiotensin II receptor blocker and partial PPARγ agonist effective for hypertension with potential for repurposing in metabolic and neurological diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: